A rapid, reproducible, and highly flexible platform to more accurately evaluate the systemic implications of cytokine release associated with novel human-targed-specific immunomodulatory drugs. It can be used to quickly and accurately select leads based on efficacy as well as toxicity caused by cytokine release.
CRS Evaluation studies can provide valuable information for:
Compare different lead candidates
Optimize dose range for tumor shrinkage or removal of target.
Determine which molecule/dosage provides minimal toxicity by using one PBMC donor for the study
Test the optimal dosages against the diversity of the population by using multiple PBMC donors in the study.
Cytokines are a part of the innate immune system. A number of factors can cause cytokines to be triggered, but when a mass release of cytokines occurs, iti s known as a cytokine storm. Cytokine storm creates a toxic environment that in extreme situations can be lethal.
For information about what cytokine release syndrome has to do with drug development, watch the "What is CRS?" video.
NSG-MHC class I/II DKO
Adult PBMC (5 to 20x106) from single or multiple donors
|Groups||4-5 mice/arm; 6-10 days/study|
Currently JAX Mice strain information sheets are experiencing technical difficulties. Please contact JAX Technical Information Scientists for strain questions. firstname.lastname@example.org | 1.800.422.6423 (US) | 1.207.288.5845 (International)